Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 11/20 | 0.35 |
| ▸ | MMP9 | P14780 | 11/20 | 0.35 |
| ▸ | MMP8 | P22894 | 10/20 | 0.35 |
| ▸ | MMP13 | P45452 | 10/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9301787 | 0.87 | CYP2C19 (0.41) | CYP2C19LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7803894 | 0.86 | CYP2C19 (0.40) | CYP2C19LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7813714 | 0.86 | CYP2C19 (0.39) | CYP2C19LMNAKMT2AALDH1A1NPC1 | |
| SCHEMBL7775183 | 0.84 | CYP2C19 (0.51) | CYP2C19LMNAKMT2AALDH1A1MMP2 | |
| SCHEMBL7028228 | 0.84 | SIGMAR1 (0.46) | — | |
| SCHEMBL7813558 | 0.81 | CYP2C19 (0.44) | CYP2C19LMNAKMT2AALDH1A1MMP2 | |
| SCHEMBL7775187 | 0.81 | CYP2C19 (0.51) | CYP2C19LMNAKMT2AALDH1A1MMP2 | |
| SCHEMBL7773261 | 0.79 | CYP2C19 (0.50) | CYP2C19LMNAKMT2AALDH1A1NPC1 | |
| SCHEMBL7045940 | 0.75 | CYP2C19 (0.61) | CYP2C19LMNAKMT2AMMP2MMP9 | |
| SCHEMBL9622341 | 0.75 | CYP2C19 (0.61) | CYP2C19LMNAKMT2AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0517325-B1 | Drug hapten analogues for immunoassays | JOHNSON & JOHNSON CLIN DIAG (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0685740-B1 | Separation-free specific binding assays using anti-inhibitor antibodies | JOHNSON & JOHNSON CLIN DIAG (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0517325-B1 | Drug hapten analogues for immunoassays | JOHNSON & JOHNSON CLIN DIAG (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0690071-B1 | Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase | JOHNSON & JOHNSON CLIN DIAG (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5916757-A | PROVIDES DIRECT CORRELATION OF GENERATED SIGNAL TO TARGET SPECIFIC BINDING LIGAND | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5601994-A | Immunoassay with novel labeled drug hapten analogues | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0690071-A2 | Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0685740-A2 | Separation-free specific binding assays using anti-inhibitor antibodies | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5298403-A | Having hydantoin or barbiturate nucleus | EASTMAN KODAK COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| US-5284948-A | Drug hapten analogues for immunoassays | EASTMAN KODAK COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0517326-A2 | Labeled drug hapten analogues for immunoassays | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1992-12-09 | — | — | EP | disclosed |